Objective To investigate the clinical efficacy of adjuvant intervention of Fuyuan Fuheng Decoction for chemotherapy in the treatment of patients with colorectal cancer(CRC)of spleen-kidney deficiency syndrome,and to observe its effects on cellular immune function,adverse reactions and the prognosis of CRC treated by chemotherapy.Methods From January 2021 to January 2023,a retrospective study was conducted on 120 patients with CRC of spleen-kidney deficiency syndrome admitted to the Second Affiliated Hospital of Shaanxi University of Chinese Medicine.The patients were divided into a study group and a control group according to the treatment protocols,with 60 patients in each group.The patients of the two groups were treated by radical resection of CRC,and then the control group was given mFOLFOX6 chemotherapy(5-Fluorouracil+Oxaliplatin+Calcium Folinate)while the study group was given Fuyuan Fuheng Decoction together with mFOLFOX6 chemotherapy after operation.Fourteen days constituted a cycle of treatment,and the two groups were given 12 consecutive cycles of treatment.Before and after treatment,the two groups were observed in the changes of traditional Chinese medicine(TCM)syndrome scores,cellular immune function indicators[T-lymphocyte subsets CD3+,CD4+,CD4+/CD8+and natural killer(NK)cells],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)scores,Piper's Fatigue Scale(PFS)scores of cancer-related fatigue,Karnofsky Performance Status(KPS)scores,and prognosis-related markers[carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),and lactate dehydrogenase(LDH)].After treatment,the therapeutic efficacy,the incidence of adverse reactions,and the one-year survival rate of the two groups were compared.Results(1)After 12 cycles of treatment,the overall response rate of the study group was 75.00％(45/60),which was significantly higher than that of the control group[53.33％(32/60)],the difference being statistically significant(x2=6.125,P＜0.05).(2)After treatment,the scores of TCM symptoms of fatigue and weakness,soreness and weakness in the waist and knee,poor appetite,vertigo and dizziness,and loose stools in the two groups were significantly decreased compared with those before treatment(P＜0.05),and the decrease in the study group was significantly superior to that in the control group(P＜0.01).(3)After treatment,the levels of cellular immune function indicators of peripheral T-lymphocyte subset CD3+,CD4+,CD4+/CD8+,and NK cells of the two groups were all decreased compared with those before treatment(P＜0.05),but the decrease in the study group was significantly milder than that in the control group(P＜0.01).(4)After treatment,the EORTC QLQ-C30 score and KPS score in the two groups were increased compared with those before treatment(P＜0.05),and the PFS score was decreased compared with that before treatment(P＜0.05).The increase of the EORTC QLQ-C30 score and KPS score as well as the decrease of the PFS score in the study group were significantly superior to that in the control group(P＜0.01).(5)After treatment,the serum levels of prognosis-related markers of CA199,CEA,VEGF,and LDH in the two groups were significantly decreased compared with those before treatment(P＜0.05),and the decrease in the study group was significantly superior to that in the control group(P＜0.01).(6)The incidence of adverse reactions such as nausea/vomiting,gastrointestinal reactions,thrombocytopenia,leukopenia,and erythrocytopenia in the study group was significantly lower than that in the control group(P＜0.05 or P＜0.01).(7)One year of follow-up after the completion of treatment showed that three cases in the study group and five cases in the control group fell off during the follow-up period.Among the patients who completed the follow-up,the survival rate of the study group was 96.49％(55/57),which was significantly higher than that of the control group[83.64％(46/55)],the difference being statistically significant(x2=5.223,P=0.022).Conclusion Adjuvant intervention of Fuyuan Fuheng Decoction can enhance the overall response rate of the patients with CRC treated by mFOLFOX6 chemotherapy,and is effective on improving clinical symptoms,immune function,and performance status of the patients,enhancing the quality of life,alleviating cancer-related fatigue,increasing the survival rate,reducing the incidence of adverse reactions,and then improving the prognosis of the patients.

Objective:Tumor-treating fields (TTFields) is a kind of non-invasive anti-mitotic tumor therapy, which has been approved for patients with newly diagnosed and recurrent glioblastoma. This study aims to explore the efficacy and safety of TTFields in high-grade gliomas in clinical practice settings.Methods:The clinical data of 15 patients with recurrent glioma and 9 patients with newly diagnosed high-grade glioma admitted to our center from April 2019 to January 2021 were retrospectively analyzed. All patients accepted TTFields≥1 month. Follow-up was performed for 5.3 months (ranged from 2.3 to 10.7 months); Response Assessment in Neuro-Oncology Working Group (RANO) criteria was used to evaluate the glioma responses. The progression-free survival (PFS) and overall survival (OS) were calculated according to Kaplan-Meier method. Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0) and TTFields related skin adverse reaction (dAE) criteria were used to evaluate the adverse events. Quality of life questionnaire-core 30 (QLQ-C30) and QLQ-brain cancer module (QLQ-BN20) questionnaires were used to evaluate the health-related quality of life (HRQoL). Treatment compliance was evaluated by data on the use of NovoTTF-200A devices, and calculated as a percentage of daily TTFields usage.Results:The median duration of TTFields was 4.2 months (ranged from 1.0 to 10.7 months), with a median compliance rate of 91.5% (67.0%-97.0%). TTFields was used alone in 2 patients and used with combination of chemotherapy in 22 patients. From follow-up to April 2021, 14 patients had stable symptoms and 10 had disease progression (8 died). The median PFS and OS of recurrent patients were 5.9 months ( 95%CI: 3.3-8.6 months) and 8.5 months ( 95%CI: 3.2-13.8 months), respectively; and the median PFS and OS of newly diagnosed patients were both 10.7 months (without 95%CI). The common adverse events included grading 1 dAE (58.3%) and grading 2 dAE (12.5%), without grading 3 or 4 dAE, manifested as contact or allergic dermatitis, erosion, folliculitis and ulcers. And 87.5% patients had stable HRQoL. Conclusions:The preliminary results showed that the survival of recurrent high-grade glioma patients treated by TTFields is similar to that reported in foreign literature; and the newly diagnosed patients need further survival follow-up. The patients' treatment compliance and safety are good. The dAE incidence (grading 1-2) is higher than that reported in the literature, and the toxicity was acceptable.